The Center for Strategic & International Studies (CSIS) published a new article this August titled “Understanding the U.S. Biopharmaceutical Innovation Ecosystem”. Authors Sujai Shivakumar, Tisyaketu Sirkar, and Jeffrey Depp discuss how vital the U.S. biopharmaceutical innovation system is at powering health improvements, economic output, and wealth creation, however, they also spotlight that sustaining the industry remains underappreciated. U.S. policymakers who are responding to consumer concerns of high prices are undermining the innovation system by weakening the patent system, a move that could put it at a competitive disadvantage globally, especially as China’s biopharmaceutical industry propels forward. The paper gives an overview of the U.S. drug development and approval process, the core components driving the biopharmaceutical innovation system, and the ongoing threats including the growth of the Chinese industry and new concerns around march-in rights.
See here for the full article, and here for the full report.